港股異動 | 中國有贊(8083.HK)續漲超4% 獲Ward Ferry增持1852.4萬股
格隆匯10月7日丨中國有贊(8083.HK)今日續漲,暫七日連升累漲超28%,現報1.77港元,漲4.73%,暫成交2.2億港元,最新總市值305億港元。聯交所最新資料顯示,9月30日,Ward Ferry增持有贊1852.4萬股,總金額約為2948萬港元,增持後其最新持股比例為7.09%。光大證券曾發研報指,中國有贊在上半年繼續受益於直播電商紅利,同時擔保服務、雲服務費等抽傭類產品滲透率的提升使得公司營收與GMV增速差距開始收窄。由於公司單季度期間費用率改善超出預期,且規模效應開始顯現,該行上調公司2020-2022年歸母淨利潤預測,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.